Huntington-kór: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• HTT 2
• NRF2 0
• BDNF 1
• STING 0
• AKT 0
• AMPK 1
• NLRP3 0
• SIRT1 0
• PI3K 0
• HMGB1 0
• PPAR 0
• C9orf72 0
• HDAC 0
• HIF-1 0
• HSP90 0
• NMDA 0
• TDP-43 0
• TLR4 0
• APP 0
• BCL-2 0
• CD30 0
• CFTR 1
• CTNNB1 0
• DMD 1
• ERK 0
• EZH2 0
• G6PD 0
• GLP-1 0
• GPX4 0
• IL-17 0
• JNK 0
• LRRK2 0
• MMP-9 0
• mTOR 0
• NF1 1
• PINK1 0
• PSEN1 0
• SMN1 1
• SOD1 0
• STAT3 0
• TP53 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NINDS · K99

  Post translational modifications as a therapeutic target for Huntington's Disease

  University of California-Irvine· Irvine, Egyesült Államok· 119 840 USD awarded in fiscal year 2026· until 2028. aug.

• NIH NIA · R43

  Non-Invasive Diagnostic Assays for Neurodegenerative Diseases

  Sonas Biotechnologies Inc· Eugene, Egyesült Államok· 499 745 USD awarded in fiscal year 2026· until 2027. szept.

• NIH NINDS · DP2

  RNA-Templated DNA Repair as a Genome Maintenance Pathway in Neurons

  University of Colorado Denver· Aurora, Egyesült Államok· 741 000 USD awarded in fiscal year 2026· until 2031. jún.

• NIH NINDS · R56

  The Mechanism of Trinucleotide Repeat Disease Expansions

  Ohio State University· Columbus, Egyesült Államok· 551 250 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NINDS · RM1

  DECIPHERING THE MOLECULAR BASIS OF SOMATIC GAA-REPEAT DYNAMICS IN SCA27B

  University of Miami School of Medicine· Coral Gables, Egyesült Államok· 1 819 495 USD awarded in fiscal year 2026· until 2031. júl.

• European Commission (Horizon Europe) · HORIZON-ERC

  Ubiquitin Signaling as a Key Regulator of Aging and Neurodegeneration (UbiAge)

  Johann Wolfgang Goethe-Universitaet Frankfurt Am Main· Frankfurt Am Main, Németország· EU contribution 1 489 985 EUR· until 2032. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Litvánia· EU contribution 196 976 EUR· until 2029. márc.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  HDFACT82: Functional characterisation of CCDC82 and its interaction with FACT in Huntington’s disease

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 194 075 EUR· until 2029. febr.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Treatment of depression and cognitive decline in Huntington's Disease: Cannabinoids as a Dual Therapeutic Approach (TACHD)

  Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer· Barcelona, Spanyolország· EU contribution 194 075 EUR· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Astrocyte Exosome Cargo as a Mediator of Non-Cell-Autonomous Neurodegeneration in Huntington’s Disease (AstroExo-HD)

  Siec Badawcza Lukasiewicz - Port Polski Osrodek Rozwoju Technologii· Wrocaw, Lengyelország· EU contribution 179 006 EUR· until 2028. máj.

10 of 278 running projects, newest first. Listed amounts together: 149,0 M USD + 30,4 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 4
• Organoids 4
• CRISPR-Cas Systems 11
• Gene Expression Profiling 13
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Proteomics 10
• Metabolomics 1
• Mass Spectrometry 1
• Immunohistochemistry 2
• Liquid Biopsy 1
• Positron-Emission Tomography 10
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 6

• Network-based stratification of allele-specific expression reveals patient subgroups in Huntington's disease.

  Bioinformatics, 2026. aug.

• Integrative network pharmacology, transcriptomics, and molecular docking identify candidate Centella asiatica constituents and targets in neurodegenerative diseases.

  PLoS One, 2026. júl.

• Topological modeling of gene expression in the brain with Huntington's disease reveals selective disruption of co-expression network.

  Sci Rep, 2026. jún.

• Single-cell transcriptomics and mouse model phenotyping for biomarker screen of peripheral blood in Huntington's disease.

  Sci Rep, 2026. máj.

• Identification of key genes related to macrophages and metabolic reprogramming in myocardial infarct based on single-cell and bulk transcriptomics data and experimental validation.

  BMC Cardiovasc Disord, 2026. máj.

• Development-related gene expression disruption in the human midcingulate cortex in Huntington's disease.

  J Huntingtons Dis, 2026. máj.

• MMP9 as a shared immune-related gene in Alzheimer's and Huntington's diseases: a cross-tissue transcriptomic analysis.

  Artif Cells Nanomed Biotechnol, 2026. ápr.

• Extensive transcriptomic changes in cellular and animal models of Huntington's disease depending on the length of CAG repeats in the exon 1 of the HTT gene.

  Biochem Biophys Res Commun, 2026. ápr.

• Topology constrained nonnegative matrix factorization for time varying omic expression.

  Sci Rep, 2026. márc.

• Decoding Non-Neuronal Mechanisms and Therapeutic Targets in Huntington's Disease Through Integrative Transcriptomics and Machine Learning.

  J Mol Neurosci, 2026. jan.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.